scispace - formally typeset
M

Min Li

Publications -  12
Citations -  2839

Min Li is an academic researcher. The author has contributed to research in topics: CD8 & T cell. The author has an hindex of 6, co-authored 7 publications receiving 1638 citations.

Papers
More filters
Journal ArticleDOI

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).

TL;DR: T cell counts are reduced significantly in COVID-19 patients, and the surviving T cells appear functionally exhausted, and non-ICU patients with total T cells counts lower than 800/μL may still require urgent intervention, even in the immediate absence of more severe symptoms.
Posted ContentDOI

Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)

TL;DR: T cell counts are reduced significantly in COVID-19 patients, and the surviving T cells appear functionally exhausted, with patients in decline period showing reduced IL-6, IL-10 and TNF-α concentrations and restored T cell counts.
Journal ArticleDOI

Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.

TL;DR: In this paper, the authors retrospectively reviewed the clinical outcomes of 76 severe COVID-19 cases admitted to 2 hospitals in Wuhan, China, from December 2019 to March 2020.
Journal ArticleDOI

Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: A retrospective cohort study

TL;DR: The results demonstrated that the nomogram and Combined Index calculated from the NLR and CRP are potential and reliable predictors of COVID-19 prognosis and can triage patients at the time of admission.
Journal Article

Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells

TL;DR: Zhang et al. as discussed by the authors reviewed the clinical outcomes of 76 severe cases with COVID-19 admitted into two hospitals in Wuhan from December 2019 to March 2020 and reported that Talpha1 treatment significantly reduced mortality of severe COVID19 patients (11 11% vs 30 00%, p=0 044).